美国中重度ARDS早期管理实践差异:严重ARDS证据生成研究
该多中心观察性队列研究纳入美国29个中心2466例接受机械通气的中重度ARDS成人患者,28天院内死亡率为40.7%。初始肺保护性通气依从率为31.4%,各中心在辅助治疗使用率、方法和死亡率上存在显著差异,仅早期肺保护性通气依从性与中心标准化死亡比相关。
要点
- 中重度ARDS患者28天院内死亡率为40.7%。
- 初始肺保护性通气依从率仅31.4%,中心间差异大(0%-65%)。
- 仅早期肺保护性通气依从性与中心标准化死亡比相关。
核心结论
- 美国中重度ARDS管理存在显著的 center-to-center 差异,提示改善ARDS结局仍有机会。
- 早期肺保护性通气依从性与较低的中心死亡率相关,可能反映整体诊疗质量。
研究设计与样本
- 多中心观察性队列研究,纳入美国29个中心2016年10月1日至2017年4月30日收治的机械通气成人ARDS患者,PaO2/FiO2≤150且PEEP≥5 cm H2O,共2466例。
- 主要结局为28天院内死亡率,并评估各中心通气管理、辅助治疗使用和死亡率的差异。
主要发现
- 基线PaO2/FiO2中位数为105(四分位距78.0-129.0)。
- 28天院内死亡率为40.7%。
- 初始肺保护性通气依从率为31.4%,各中心间范围为0%-65%。
- 辅助治疗使用率各中心间范围为27.1%-96.4%,方法包括神经肌肉阻滞、俯卧位、全身激素、肺血管扩张剂和体外支持。
- 各中心死亡率范围为16.7%-73.3%,标准化死亡比(SMR)范围为0.33-1.98。
关键数值与推荐
- 肺保护性通气定义为潮气量≤6.5 mL/kg预测体重,平台压(不可用时吸气峰压)≤30 mm H2O。
- 仅中心早期肺保护性通气依从性与SMR相关。
临床怎么用
- 临床应重视并提高早期肺保护性通气的依从性,以改善中重度ARDS患者结局。
- 各中心应评估自身辅助治疗使用模式与死亡率差异,推动质量改进。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although specific interventions previously demonstrated benefit in patients with ARDS, use of these interventions is inconsistent, and patient mortality remains high. The impact of variability in center management practices on ARDS mortality rates remains unknown. RESEARCH QUESTION: What is the impact of treatment variability on mortality in patients with moderate to severe ARDS in the United States? STUDY DESIGN AND METHODS: We conducted a multicenter, observational cohort study of mechanically ventilated adults with ARDS and Pao2 to Fio2 ratio of ≤ 150 with positive end-expiratory pressure of ≥ 5 cm H2O, who were admitted to 29 US centers between October 1, 2016, and April 30, 2017. The primary outcome was 28-day in-hospital mortality. Center variation in ventilator management, adjunctive therapy use, and mortality also were assessed. RESULTS: A total of 2,466 patients were enrolled. Median baseline Pao2 to Fio2 ratio was 105 (interquartile range, 78.0-129.0). In-hospital 28-day mortality was 40.7%. Initial adherence to lung protective ventilation (LPV; tidal volume, ≤ 6.5 mL/kg predicted body weight; plateau pressure, or when unavailable, peak inspiratory pressure, ≤ 30 mm H2O) was 31.4% and varied between centers (0%-65%), as did rates of adjunctive therapy use (27.1%-96.4%), methods used (neuromuscular blockade, prone positioning, systemic steroids, pulmonary vasodilators, and extracorporeal support), and mortality (16.7%-73.3%). Center standardized mortality ratios (SMRs), calculated using baseline patient-level characteristics to derive expected mortality rate, ranged from 0.33 to 1.98. Of the treatment-level factors explored, only center adherence to early LPV was correlated with SMR. INTERPRETATION: Substantial center-to-center variability exists in ARDS management, suggesting that further opportunities for improving ARDS outcomes exist. Early adherence to LPV was associated with lower center mortality and may be a surrogate for overall quality of care processes. Future collaboration is needed to identify additional treatment-level factors influencing center-level outcomes. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03021824; URL: www.clinicaltrials.gov.
引用
- Qadir N, Bartz RR, Cooter ML, et al. Variation in Early Management Practices in Moderate-to-Severe ARDS in the United States: The Severe ARDS: Generating Evidence Study. Chest. 2021. PMID: 34089739. doi:10.1016/j.chest.2021.05.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。